Advertisement

Topics

STAT Plus: Ziopharm claims FDA loves its brain cancer gene therapy, so why is the phase 3 study taking so long to start?

04:30 EDT 3 Aug 2017 | STAT

Four months after Ziopharm Oncology said FDA gave “positive guidance” on the design of a phase 3 clinical trial for brain cancer, it has offered no details.

Original Article: STAT Plus: Ziopharm claims FDA loves its brain cancer gene therapy, so why is the phase 3 study taking so long to start?

NEXT ARTICLE

More From BioPortfolio on "STAT Plus: Ziopharm claims FDA loves its brain cancer gene therapy, so why is the phase 3 study taking so long to start?"

Quick Search
Advertisement
 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...